Acetylcholine-norepinephrine interactions and their implications for the effects

$311,870P50FY2015DANIH

Yale University, New Haven CT

Investigators

Linked publications, trials & patents

Paper 37396408 Paper 36107715 Paper 35737132 Paper 35727299 Paper 35359158 Paper 34997190 Paper 34965199 Paper 33600842 Paper 32152625 Paper 31364813 Paper 31347245 Paper 31341936 Paper 31275802 Paper 31269510 Paper 31058288 Paper 30895878 Paper 30707118 Paper 30239953 Paper 30222189 Paper 30016463 Paper 29878501 Paper 29863382 Paper 29746147 Paper 29692206 Paper 29527591 Paper 29472646 Paper 29347837 Paper 29059410 Paper 28659613 Paper 28473910 Paper 28440105 Paper 28339616 Paper 28264149 Paper 28217246 Paper 28212516 Paper 28028603 Paper 27743899 Paper 27670870 Paper 27613893 Paper 27499723 Paper 27471021 Paper 27439453 Paper 27354839 Paper 27026829 Paper 26987699 Paper 26963956 Paper 26946448 Paper 26918114 Paper 26888199 Paper 26718905 Paper 26570992 Paper 26503700 Paper 26471256 Paper 26446070 Paper 26413165 Paper 26146014 Paper 26130105 Paper 25904837 Paper 25879669 Paper 25762760 Paper 25762757 Paper 25762750 Paper 25762746 Paper 25634160 Paper 25582289 Paper 25564239 Paper 25537344 Paper 25516371 Paper 25505336 Paper 25401293 Paper 25347015 Paper 25288485 Paper 25204986 Paper 25133506 Paper 25066781 Paper 25064023 Paper 24983212 Paper 24916157 Paper 24854801 Paper 24847667 Paper 24817825 Paper 24777394 Paper 24742621 Paper 24727731 Paper 24715505 Paper 24600335 Paper 24566280 Paper 24533257 Paper 24439692 Paper 23969142 Paper 23963311 Paper 23959137 Paper 23930623 Paper 23891776 Paper 23878146 Paper 23721534 Paper 23651795 Trial NCT02800928 Trial NCT01904526 Trial NCT00773357

Abstract

An important risk factor for relapse to smoking is female gender. Women have less success in unaided quit attempts and may be less responsive to nicotine replacement therapies than men. Higher stress reactivity and prevalence of mood-related symptoms are increasingly recognized as important for the increased difficulty in quitting experienced by women. Both norepinephrine and acetylcholine are critical neurotransmitters regulating activity in brain circuits essential for stress-related behaviors, including the amygdala-prefrontal cortical circuit. In keeping with the overarching theme ofthe Yale-SCOR related to sex differences in noradrenergic control of smoking behavior, we hypothesize that the disparity in susceptibility to smoking relapse between women and men may be due to underlying differences in cholinergic- noradrenergic interactions. Thus, it is important to examine these mechanisms in an animal model with input and feedback from Projects II and III to determine what alterations in neurochemistry might underlie these differences and to provide an integrated understanding ofthe neurobiological basis for sex differences in smoking. The primary aims of Project I are to identify the brain areas regulated by guanfacine and nicotinic drugs under conditions related to stress-reactivity (Aim 1), to determine whether stimulation ofthe noradrenergic system with guanfacine can decrease stress reactivity (Aim 2) and dopamine dependent behaviors (Aim 3) in a hypercholinergic model of increased stress reactivity in male and female mice. This project will also determine whether the effects of guanfacine on anxiety and nicotine reinforcement depend on expression of nAChRs (Aim 4). This basic science project is designed to identify neuronal mechanisms underlying similar effects of guanfacine to decrease smoking in female and male human subjects, but to decrease stress reactivity only in women. It is also designed to identify neurochemical mechanisms underlying the effects of guanfacine on the cholinergic and dopaminergic systems. The findings from Project I will be integrated with those from Projects II and III of the Yale-SCOR to inform the development of novel gender-sensitive therapeutics for smoking cessation.

View original record on NIH RePORTER →